The Effect of Prolonged Glucosamine Usage on HbA1c Levels and New-Onset Diabetes Mellitus in Overweight and Obese Middle-Aged Women by Gommans, Y.M.M. (Yvonne) et al.
1 
 
Title: The effect of prolonged glucosamine usage on HbA1c levels and new-onset diabetes 
mellitus in overweight and obese middle-aged women  
Running head: The effect of prolonged glucosamine usage in overweight middle-aged women. 
 
Authors: Y.M.M. Gommans BSca, J. Runhaar PhDa, M.L. Jacobs MD, PhDa, S.M.A. Bierma-
Zeinstra PhDa,b 
 
Affiliations: a Erasmus University Medical Center Rotterdam, department of General Practice. 
b Erasmus University Medical Center Rotterdam, department of Orthopedics 
 
Corresponding author: 
J. Runhaar 
Erasmus MC University Medical Center Rotterdam 
Room NA 1906 
PO-box 2040 
3000 CA Rotterdam, The Netherlands  
Tel.: 31-10-7044192; Fax: 31-10-7044766.  
E-mail address: j.runhaar@erasmusmc.nl. 
 
Type of manuscript: Clinical Research Study 
Word count: 2967 
Keywords: Glucosamine; Diabetes Mellitus; HbA1c; Knee osteoarthritis; Overweight; 
Randomized Controlled Trial 
2 
 
Funding: The PROOF study has been funded by ZonMw, The Netherlands Organisation for 
Health Research and Development, the European Union's Seventh Framework Programme D-
BOARD (grant agreement 305815), and received partial funding from a program grant of the 
Dutch Arthritis Foundation for their centre of excellence "Osteoarthritis in primary care" (grant 
number 120520001). 
 
Conflict of interest: The authors declare no conflict of interest 
 
Contributorship statement: J. Runhaar and S.M.A. Bierma-Zeinstra were involved in the study 
design. All authors contributed to the analysis and interpretation of the data and were involved in 
drafting and critically revising the content of the manuscript.  
  
3 
 
Abstract 
Objective. The aim of the present study was to evaluate the effect of a 2.5 year glucosamine 
sulphate intervention on haemoglobin A1c (HbA1c) levels and the incidence of new-onset 
diabetes mellitus over 6.5 years in middle-aged women with a BMI ≥27 kg/m2.  
Methods. In total, 407 women were randomized into either oral crystalline glucosamine sulphate 
or placebo. At baseline, 1 year, 2.5 years and 6.5 years a blood sample for the HbA1c level was 
drawn and a questionnaires were taken. After 6.5 years there was missing data for some 
variables, therefore multiple imputation was used. With the imputed data, a generalized 
estimating equation was performed to analyze the effect of glucosamine sulphate usage over 6.5 
years. Finally, these analyses were rerun for the two subgroups of participants with and without 
high HbA1c level (≥42 mmol/mol) at baseline.  
Results. There was no significant effect of a 2.5 year glucosamine sulphate intervention on mean 
HbA1c level or on obtaining a high HbA1c level and/or new-onset diabetes mellitus over 6.5 
years. The subgroup analyses of participants with and without high HbA1c level at baseline were 
also not statistically significant. However, participants with a high HbA1c level at baseline had 
higher ORs compared with the participants with a normal HbA1c at baseline.  
Conclusions. There was no effect of glucosamine sulphate on mean HbA1c level nor on 
obtaining a high HbA1c level and/or new-onset diabetes mellitus over 6.5 years, especially in 
participants with a normal HbA1c level at baseline.  
 
Introduction 
Glucosamine is a commonly used treatment for osteoarthritis (OA), although the evidence is 
limited.1 It is an amino-monosaccharide derivative of glucose and a precursor of the 
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glycosaminoglycans and proteoglycans that make up articular cartilage. Glucosamine is 
metabolized by the hexosamine pathway, both glucose and glucosamine enter this pathway as 
glucosamine-6-phosphate.2 It is a dietary supplement that is available over-the-counter and is 
considered to be safe; no fatal or serious adverse events have been reported.3 However, there are 
concerns that it might adversely affect the glucose metabolism and causes insulin resistance, but 
this has only been proven in animal studies.4 Recent studies suggest that it may also affect the 
glucose transport and insulin resistance in humans, especially among patients with impaired 
glucose tolerance.5-7 However, all these studies had considerable heterogeneity in terms of dose, 
route and duration of glucosamine administration. This warrants further research, particularly in 
subjects with an impaired glucose tolerance or insulin resistance.5 
To diagnose diabetes, haemoglobin A1c (HbA1c) levels can be used. It provides a reliable 
measurement of chronic glycaemia and is elevated when there is a long-term hyperglycaemia 
over the preceding two to three months.8 It also correlates well with the risk of diabetes 
complications. Diabetes mellitus is diagnosed with a HbA1c level of ≥48 mmol/mol. Risk factors 
for diabetes development are elevated levels of triglycerides, blood pressure, BMI, and family 
history of diabetes. These risk factors have to be taken into account when considering treatment 
intervention at a HbA1c level of ≥42 mmol/mol.9 The most prevalent risk factors for OA are 
overweight or obesity, a higher age, and the female gender.10, 11 This means that some risk 
factors are identical for both diabetes mellitus and OA, and some people are therefore at 
increased risk for both diseases.  
The main objectives of this study was to evaluate the effect of a 2.5 year glucosamine 
intervention on mean HbA1c levels and the risk of obtaining a high HbA1c level (≥42 
mmol/mol) and/or new-onset diabetes mellitus over 6.5 years in middle-aged women with a BMI 
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≥27 kg/m2. The second objective was the evaluation of the effect of the intervention on mean 
HbA1c level and the risk of obtaining a high HbA1c level (≥42 mmol/mol) and/or new-onset 
diabetes mellitus over 6.5 years in women with and without high HbA1c level (≥42 mmol/mol) 
at baseline.  
 
Methods 
The present study used data of the PROOF study (PRrevention of knee Osteoarthritis in 
Overweight Females, IS RCTN 42823086), a randomized controlled trial funded by ZonMw, 
The Netherlands Organisation for Health Research and Development. In a 2x2 factorial design, 
the effects of glucosamine sulphate (double blind, placebo-controlled) and of a diet and exercise 
program on the development on knee OA were evaluated. The study was approved by the 
Medical Ethics Committee of Erasmus University Medical Centre Rotterdam. A full description 
of the study protocol can be found elsewhere.12  
 
Study sample 
All women between 50 and 60 years without major comorbidities and who were registered at a 
participating general practitioner (GP) in the region of Rotterdam, the Netherlands, were 
contacted. Interested women with a reported BMI ≥ 27 kg/m2 were contacted by phone to check 
all inclusion criteria. Inclusion criteria were that all women had to be free of knee OA according 
to the ACR-criteria13, were not under treatment for knee complaints, were free of MRI 
contraindications, were free of rheumatic diseases, were not using walking-aids, had mastered 
the Dutch language and had not used oral glucosamine in the past 6 months. All women who 
were willing to participate were invited for baseline measurements and randomization between 
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July 2006 and May 2009. Out of 6.691 women that were contacted, a total of 407 were interested 
in participating and fulfilled the inclusion criteria.12 The participants were randomized to 
glucosamine or placebo one-on-one using a blocked randomization list with block size 20. 
Randomization for the diet and exercise program or control group was also done using block 
randomization with block size 20.12 
 
Outcome measures 
Height, weight and waist circumference were measured at baseline. Additionally, a blood sample 
was drawn for HbA1c level (mmol/mol) analysis, a SQUASH14 (Short Questionnaire to Assess 
Health-enhancing physical activity) questionnaire was taken and there were questions to obtain 
information about their comorbidities.12 After 1 year, 2.5 years and 6.5 years these measurements 
were repeated.   
 
Crystalline glucosamine sulphate versus placebo 
The study drugs were provided by Rottapharm Madaus in identical packaging. The participants 
and research staff were blinded for allocation throughout the whole study. Rottapharm Madaus 
was not involved in study design, data collection, or statistical analyses. All participants were 
asked to consume one sachet of 1500 mg of the study drug (powder) a day.12 They only received 
the study drug in the first 2.5 years, after which they were observed for the remaining 4 years.  
 
Analyses 
The primary outcome measures were defined as mean HbA1c level and High HbA1c/DM. A 
normal HbA1c level was set at a level below 42 mmol/mol particularly because the participants 
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had risk factors for both diseases. The variable High HbA1c/DM was defined as having a high 
HbA1c level (≥ 42 mmol/mol) at a specific follow up moment or having a ‘positive diabetes 
mellitus status’. A positive diabetes mellitus status was interpreted as having the diagnosis 
diabetes mellitus or receiving treatment for diabetes mellitus according to the questionnaire. 
Patients with a positive diabetes mellitus status at an early follow up moment and missing data at 
a later follow up moment were also defined as ‘positive’, considering the fact that diabetes 
mellitus is irreversible.  
The baseline characteristics were presented as means ± standard deviation (SD) for numerical 
variables and percentages for categorical variables. Baseline differences were tested using t-tests 
for numerical variables and Fisher’s exact test for categorical variables. 
Multiple imputation was performed to estimate the missing data to improve the validity of the 
study.15 Fifty imputed datasets were used, method was set to automated selection of linear 
regression or predictive mean matching, maximum iterations were set to 20 and a maximum of 
150 parameters per variable was used.16 Variables with more than 50% missing date were 
excluded from the multiple imputation, because of computational problems.15, 17 This made it 
impossible to impute the variable about their diabetes mellitus status. In order to still use this 
variable in the analyses we only used the women with a positive diabetes mellitus status, 
meaning that missing data was filled in as a negative diabetes mellitus. The variables that were 
imputed by SPSS are shown in tables and graphs in the appendix. 
A generalized estimating equation (GEE) with an unstructured correlation matrix was used to 
analyze the effect of glucosamine usage, using the 1 year, 2.5 year and 6.5 year measurements as 
repeated measurements. A linear GEE was used to analyze intervention effects on mean HbA1c 
level over 6.5 years. A binary logistic GEE was used to analyze the risk at obtaining a High 
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HbA1c/DM over 6.5 years. Both analyses were rerun in participants with (≥ 42 mmol/mol) and 
without elevated HbA1c level at baseline (< 42 mmol/mol). All analyses were adjusted for 
possible confounders (HbA1c level at baseline,  smoking at baseline, education level, BMI, 
SQUASH at baseline and change over 6.5 years, change in waist circumference, ethnicity, 
cardiovascular diseases at baseline, and season change of HbA1c 18) and the randomized groups 
of the diet and exercise program. A Pearson correlation matrix was calculated to measure any 
linear correlation between two variables, but there were none with a correlation under 0.7 and 
therefore there was no multi-collinearity.19 When a GEE was impossible to run in an 
unstructured correlation matrix, variables that were the least significantly contributing to the 
GEE were removed using backward selection.  
Using complete data (after imputation) of all 407 subjects, we had >90% power to detect a 1.0 
mmol/mol difference between groups and 80% power to detect a difference of 11% (equals mean 
over time in placebo group) vs. 15.5% in proportion of subjects reaching High HbA1c/DM. A 
difference of 5 mmol/mol is considered clinically relevant.20, 21 
All analyses were performed using SPSS 21, results from the GEE analyses are expressed as 
odds ratios (ORs) with associated 95% confidence intervals (CI) and significance level. Values 
of p < 0.05 were considered statistically significant.  
 
Results 
For the present study, all women with diabetes mellitus at baseline were excluded (N=29, 7.1%) 
from all statistical analyses, because the aim of the study was to analyze whether or not this 
diagnosis would develop during the follow up period. There was one outlier with a HbA1c level 
of 130.6 mmol/mol and was therefore excluded from all analyses. There were no significant 
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differences between the participants that were lost to follow up (drop-outs) and those that 
completed the study, as shown in Table 1. 
 
Table 1 Baseline characteristics of the missing and available data (mean ± st.dev or percentage) 
 Missing (N = 132) Available (N = 245) P-values 
Age (years) 55.7 (SD±3.1) 55.7 (SD±3.2) 0.85 
BMI (kg/m2) 32.3 (SD±3.8) 32.1 (SD±4.1) 0.70 
HbA1c (mmol/ml) 37.8 (SD±4.5) 38.2 (SD±3.9) 0.34 
HbA1c ≥42 mmol/mol (%) 14.9% 14.2% 0.87 
HbA1c ≥48 mmol/mol (%) 2.5% 1.7% 0.69 
Total cholesterol (mmol/L) 6.0 (SD±1.2) 6.1 (SD±1.1) 0.45 
Smoking (%) 20.6% 16.4% 0.32 
Cardiovascular disease (%) 3.8% 3.3% 0.77 
Systolic blood pressure (mmHg) 148.0 (SD±21.6) 106.1 (SD±21.7) 0.22 
Diastolic blood pressure (mmHg) 95.2 (SD±11.7) 92.8 (SD±11.7) 0.07 
Waist circumference (cm) 105.1 (SD±9.4) 106.1 (SD±9.8) 0.32 
SQUASH* 6575.8 (SD±3799.4) 7049.6 (SD±3703.7) 0.24 
Obesity (%)**  69.7% 63.3% 0.26 
* SQUASH: validated physical activity questionnaire. 
** Obesity: BMI ≥ 30. 
 
Baseline characteristics 
The study population consisted of 94.1% Caucasian women. At baseline there were no 
significant differences between the glucosamine and placebo group, as shown in Table 2.  
 
Table 2 Baseline characteristics between intervention groups (mean ± st.dev or percentage) 
 Placebo (N=185) Glucosamine (N=192) P-values 
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Age (years) 55.7 (SD±3.2) 55.7 (SD±3.1) 0.99 
BMI (kg/m2) 32.3 (SD±4.3) 32.1 (SD±3.7) 0.52 
Caucasian origin (%) 95.6% 92.7% 0.35 
High education level (%) 31.0% 34.5% 0.49 
HbA1c (mmol/mol) 37.8 (SD±3.8) 38.3 (SD±4.4) 0.23 
HbA1c ≥42 mmol/mol (%) 14.8% 14.0% 0.88 
HbA1c ≥48 mmol/mol (%) 0.6% 3.4% 0.12 
Total cholesterol (mmol/L) 6.0 (SD±1.1) 6.1 (SD±1.1) 0.30 
Smoking (%) 14.8% 20.8% 0.14 
Cardiovascular disease (%) 3.8% 3.1% 0.78 
Systolic blood pressure (mmHg) 145.4 (SD±20.1) 146.8 (SD±23.2) 0.55 
Diastolic blood pressure (mmHg) 93.5 (SD±11.1) 93.8 (SD±12.3) 0.80 
Waist circumference (cm) 105.5 (SD±9.6) 105.5 (SD±9.8) 0.65 
SQUASH* 6946.0 (SD±3905.5) 6823.6 (SD±3581.0) 0.75 
Obesity (%)** 65.4% 65.6% 1.00 
* SQUASH: validated physical activity questionnaire. 
** Obesity: BMI ≥ 30. 
 
HbA1c levels during follow up 
Mean HbA1c levels were available for 354 women (94%) at baseline, 313 (83%) after 1 year, 
325 (86%) after 2.5 years and 209 (55%) after 6.5 years. Mean HbA1c levels in the placebo 
group were 37.8 (SD±3.8) at baseline, 38.2 (SD±3.4) after 1 year, 38.1 (SD±3.7) after 2.5 years 
and 38.3 (SD±4.2) after 6.5 years. In the glucosamine group mean HbA1c levels this was 
respectively 38.3 (SD±4.4), 39.1 (SD±5.5), 39.1 (SD±6.2) and 38.7 (SD±5.4). These results are 
shown in Table 3.  
High HbA1c/DM was available for 355 women (94%) after 1 year, 330 (88%) after 2.5 years and 
245 (65%) after 6.5 years. Table 3 also shows that the percentage of participants with High 
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HbA1c/DM in the placebo group was 12.6% after 1 year, 11.0% after 2.5 years and 8.3% after 
6.5 years. For the glucosamine group this was 18.3%, 18.6% and 15.2% respectively.  
 
Table 3 HbA1c levels and  participants  with High HbA1c/DM during follow up (mean ± st.dev 
or percentage) 
  Total Placebo Glucosamine 
Baseline N 354 176 178 
 HbA1c (mmol/mol) 38.1 (SD±4.1) 37.8 (SD±3.8) 38.3 (SD±4.4) 
 N 354 176 178 
 High HbA1c* (%) 14.4% 14.8% 14.0% 
1 year N 313 155 158 
 HbA1c (mmol/mol) 38.6 (SD±4.6) 38.2 (SD±3.4) 39.1 (SD±5.5) 
 N 355 175 180 
 High HbA1c/DM ** (%) 15.5% 12.6% 18.3% 
2.5 years N 325  161 164 
 HbA1c (mmol/mol) 38.6 (SD±5.1) 38.1 (SD±3.7) 39.1 (SD±6.2) 
 N 330 163 167 
 High HbA1c/DM ** (%) 14.8% 11.0% 18.6% 
6.5 years N 209 106 103 
 HbA1c (mmol/mol) 38.5 (SD±4.8) 38.3 (SD±4.2) 38.7 (SD±5.4) 
 N 245 120 125 
 High HbA1c/DM ** (%) 11.8% 8.3% 15.2% 
* HbA1c level ≥ 42 mmol/mol; at baseline all women with diabetes mellitus were excluded. 
** HbA1c ≥ 42 mmol/mol at specific follow-up moment and/or positive diabetes mellitus status. 
 
Generalized estimating equation 
Table 4 and 5 show all ORs obtained from the multiple imputation sets with corresponding 95% 
confidence interval (95% CI) and significance level. The glucosamine intervention showed 
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higher mean HbA1c levels over 6.5 years and a higher risk of obtaining High HbA1c/DM over 
6.5 years among all subjects, but these differences did not reach statistical significance. Both 
analyses were rerun for the subgroups with and without elevated HbA1c level at baseline. These 
ORs also did not show significant differences between the glucosamine and placebo group over 
6.5 years. However, the participants with a normal HbA1c level at baseline had an OR closer to 
one compared with the participants with a high HbA1c level at baseline.  
The binary logistic GEE analysis of the subgroup with a high HbA1c at baseline was impossible 
to run in an unstructured correlation and backward selection was used. This resulted in an OR of 
2.65 (95% CI 0.81-8.66, P=0.11).  
Because of the relatively high percentage of participants with High HbA1c/DM after 2.5 years in 
the glucosamine group, as showed in Table 3, additional GEEs were performed to evaluate the 
effect of the glucosamine sulphate intervention on the mean HbA1c level and on obtaining High 
HbA1c/DM over 2.5 years. These analyses had approximately the same ORs and significance 
level compared with the analyses over 6.5 years. The results of these analyses over 2.5 years can 
be found in tables added to the Appendix.  
 
Table 4 Linear generalized estimating equation on mean HbA1c level after multiple imputation 
over 6.5 years 
  Glucosamine versus placebo group 
 N OR*  95% CI Sig. 
All participants  377 1.40 1.77-3.46 0.47 
Participants with a normal HbA1c at baseline 309-319† 1.06 0.44-2.56 0.89 
Participants with a high HbA1c at baseline 58-68† 24.36 0.02-27805.80 0.37 
* Adjusted for lifestyle intervention group, HbA1c level at baseline, season change of HbA1c, 
cardiovascular diseases at baseline, ethnicity, smoking at baseline, education level, BMI at 
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baseline, age at baseline, SQUASH at baseline, change in SQUASH after 6.5 years, change in 
waist circumference after 6.5 years.  
†Number of participants depending on imputation number. 
 
Table 5 Binary logistic generalized estimating equation on High HbA1c/DM after multiple 
imputation over 6.5 years 
  Glucosamine versus placebo group 
 N OR* 95% CI Sig. 
Total participants 377 1.28 0.79-2.07 0.31 
Participants with a normal HbA1c at baseline 309-319† 1.24 0.71-2.14 0.45 
Participants with a high HbA1c at baseline 58-68† 2.65** 0.81-8.66 0.11 
* Adjusted for lifestyle intervention group, HbA1c level at baseline, season change of HbA1c, 
cardiovascular diseases at baseline, ethnicity, smoking at baseline, education level, BMI at 
baseline, age at baseline, SQUASH at baseline, change in SQUASH after 6.5 years, change in 
waist circumference after 6.5 years.  
** Adjusted for lifestyle intervention group, HbA1c level at baseline, season change of HbA1c, 
ethnicity, smoking at baseline, BMI at baseline, change in SQUASH after 6.5 years and change 
in waist circumference after 6.5 years.  
†Number of participants depending on imputation number. 
 
Discussion 
This study evaluated the effects of glucosamine sulphate on mean HbA1c levels and the risk of 
obtaining High HbA1c/DM over 6.5 years in overweight and obese middle-aged women. During 
the last four years of the study the participants did not use glucosamine sulphate, making it 
possible to observe any long term effects of glucosamine sulphate on the glucose metabolism 
after discontinuation of the study drug.  
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Although there was a trend towards a higher mean HbA1c level and a higher risk of obtaining 
High HbA1c/DM over 6.5 years for the glucosamine sulphate group, there was no statistically 
significant effect of the intervention on either mean HbA1c level or on the risk of obtaining High 
HbA1c/DM over 6.5 years. In the subgroup analyses, in participants with and without elevated 
HbA1c level, there was no statistically significant effect of glucosamine sulphate on mean 
HbA1c level or on the risk of obtaining High HbA1c/DM over 6.5 years. However, the subgroup 
analysis in participants with a high HbA1c at baseline had a high OR in both the linear and 
binary logistic GEE, respectively 24.36 (95% CI 0.02-27805.80, P=0.37) and 2.65 (95% CI 0.81-
8.66, P=0.11). These results have a broad 95% CI interval and this could be due to the small 
number of participants in this subgroup, approximately 58-68 participants depending on the 
imputation number, leading to lack of statistical power and this makes it impossible to state with 
certainty whether there is no truly intervention effect.  
In literature, there are two studies that also investigated the long term effects of glucosamine on 
glucose metabolism.7 Both studies, by Pavelká et al. 22 and Reginster et al. 23, monitored the 
fasting plasma glucose level as secondary outcome measure. After three years of glucosamine 
supplementation there was no effect of glucosamine on the fasting plasma glucose level in either 
study. However, the participants in both these studies were not at an increased risk for diabetes 
mellitus compared to the population of the present study. The systematic review of Simon et al. 
also pointed out that there was no study that specifically addressed the long-term safety of 
glucosamine in diabetic or pre-diabetic subjects.7  
Studies that evaluated the effect of glucosamine on the HbA1c level, instead of fasting plasma 
glucose, had a variation in this measurement making it hard to compare the HbA1c levels.6, 24, 25 
In the United States the HbA1c level is already used to diagnose diabetes mellitus and it can be 
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used in studies to evaluate the glucose status.20, 21 Considering this variance a new variable was 
made, in contrast with previous studies, to analyze the effect of glucosamine on obtaining a high 
HbA1c level and/or new-onset diabetes mellitus over 6.5 years.  
Strengths of this study includes the repeated measures that were used in the analyses, while this 
gives a reliable indication of the intervention effect over 6.5 years instead of after 6.5 years. 
Other strengths were the large number of participants, the HbA1c levels that were measured 
during glucosamine sulphate usage and the specific high risk group of participants that used the 
study drugs. 
On the contrary, a limitation of the present study was the impossibility to impute the variable 
about the participants diabetes mellitus status. As a result, we might have underestimated the 
effect while participants with a normal HbA1c level can still have diabetes mellitus. Secondly, 
there was a slight variation in the course of mean HbA1c level and High HbA1c/DM during 
follow up between the original data and imputed data. These differences could have been due to 
the large amount of missing data after 6.5 years, the withdrawing of participants not at random or 
due to unknown or unavailable predictors for the analysis.15 
Taking all results into consideration it is important that future studies will be carried out to 
investigate whether there is a significant effect of glucosamine on the glucose metabolism, 
especially in participants with a high risk for developing diabetes mellitus such as having a high 
HbA1c level at baseline. Although there was no statistically significant effect of glucosamine 
sulphate on mean HbA1c nor on the risk on obtaining High HbA1c/DM, a possible effect was 
seen in participants with a high HbA1c level at baseline. These analyses had high ORs that were 
not statistically significant, but this subgroup was too small to draw definitive conclusions due to 
lack of power.  
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In conclusion, there is no significant effect of a 2.5 year glucosamine sulphate intervention on 
mean HbA1c level or on obtaining a high HbA1c level and/or new-onset diabetes mellitus over 
2.5 nor over 6.5 years in obese and overweight middle-aged women. More specifically, there was 
no intervention effect of glucosamine sulphate in the subgroup with participants with a normal 
HbA1c level at baseline. We cannot rule out a possible effect in the subgroup of participants with 
a high HbA1c level at baseline, although these results were also not statistically significant. 
However, this subgroup lacked power to state with certainty that there is no effect of the 
intervention. Future studies should therefore focus on subjects with an increased risk of 
developing diabetes mellitus. This indicates that for now glucosamine sulphate is safe to use in 
terms of its safety profile, certainly in participants with a normal HbA1c level at baseline.    
In conclusion, there is no significant effect of a 2.5 year glucosamine sulphate intervention on 
mean HbA1c level or on obtaining a high HbA1c level and/or new-onset diabetes mellitus over 
2.5 nor over 6.5 years in obese and overweight middle-aged women. More specifically, there was 
no effect of glucosamine sulphate in the subgroup with participants with a normal HbA1c level 
at baseline. We cannot rule out a possible effect in the subgroup of participants with a high 
HbA1c level at baseline, although these results were also not statistically significant. However, 
this subgroup lacked power to state with certainty that there is no effect. Future studies should 
therefore focus on subjects with an increased risk of developing diabetes mellitus. This indicates 
that glucosamine sulphate is safe to use, certainly in participants with a normal HbA1c level at 
baseline.    
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